Table 4. Incidence of relapses and disease-related deaths according to the concomitant detection of CK-19 mRNA(+) CTCs and DTCs pre-chemotherapy.
| DTC/CTC status |
Clinical relapses
|
Deaths
|
||||
|---|---|---|---|---|---|---|
| Yes | No | P-value | Yes | No | P-value | |
| CTC(+)/DTC(+) (n=88) | 24 (27.3%) | 64 (72.7%) | 15 (17.0%) | 73 (83.0%) | ||
| CTC(−)/DTC(−) (n=67) | 10 (14.9%) | 57 (85.1%) | 0.066 | 3 (4.5%) | 64 (95.5%) | 0.016 |
| Other combinationsa (n=10) | 3 (30.0%) | 7 (70.0%) | 2 (20.0%) | 16 (80.0%) | ||
CK-19=cytokeratin-19; CTC=circulating tumour cell; DTC=disseminated tumour cell.
a
(CTC(+)/DTC(−) or CTC(−)/DTC(+)).
Significant P-values are shown in bold.